The challenge of implementing high-throughput technologies in clinical trials

Pharmacogenomics

Volumn 6, Issue 4, 2005, Pages 435-439

  Mocellin, Simone ^a   Marincola, Francesco M ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Clinical trials; Functional genomics; High throughput technology; Microarray; Pharmacogenomics; Proteomics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GENOMIC DNA;

ARTICLE; CLINICAL RESEARCH; CLINICAL STUDY; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND; DNA EXTRACTION; DRUG RESPONSE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME; MEDICAL TECHNOLOGY; PHARMACOGENETICS; PROTEIN MICROARRAY;

BIOLOGICAL MARKERS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; RESEARCH DESIGN;

EID: 21444452419     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.4.435     Document Type: Article

References (19)

1. Horig H, Pullman W: From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference. J. Transl. Med. 2, 44 (2004).
2. Lotze MT, Wang E, Marincola FM et al.: Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J. Immunother. 28, 79-119 (2005).
3. Mocellin S, Provenzano M, Rossi CR, Pilati P, Nitti D, Lise M: DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. Ann. Surg. 241, 16-26 (2005).
4. Shergill IS, Shergill NK, Arya M, Patel HR: Tissue microarrays: a current medical research tool. Curr. Med. Res. Opin. 20, 707-712 (2004).
5. Mocellin S, Riccardo Rossi C, Traldi P, Nitti D, Lise M: Molecular oncology in the post-genomic era: the challenge of proteomics. Trends Mol. Med. 10, 24-32 (2004).
6. Vanhecke D, Janitz M: High-throughput gene silencing using cell arrays. Oncogene 23, 8353-8358 (2004).
7. Butcher EC, Berg EL, Kunkel EJ: Systems biology in drug discovery. Nature Biotechnol. 22, 1253-1259 (2004).
8. Celis JE, Gromov P: Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3, 9-15 (2003).
9. Snyderman R: The clinical researcher - an "emerging" species. JAMA 291, 882-883 (2004).
10. Rees J: Complex disease and the new clinical sciences. Science 296, 698-700 (2002).
11. Bialek W, Botstein D: Introductory science and mathematics education for 21st-Century biologists. Science 303, 788-790 (2004).
12. Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62, 3581-3586 (2002).
13. Panelli MC, Wang E, Phan G et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 3, research0035 (2002).
14. Panelli MC, White R, Foster M et al.: Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J. Transl. Med. 2, 17 (2004).
15. Mankoff SP, Brander C, Ferrone S, Marincola FM: Lost in translation: obstacles to translational medicine. J. Transl. Med. 2, 14 (2004).
16. Kotchen TA, Lindquist T, Malik K, Ehrenfeld E: NIH peer review of grant applications for clinical research. JAMA 291, 836-843 (2004).
17. Baselga J, Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. (epub ahead of print) (2005).
18. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909-915 (2004).
19. Roadblocks to cancer cures. Nature Med. 10, 1003 (2004).